BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020
Net Income	-21.58	-6.81	-26.79	-34.4	-17.24	-5.4
Depreciation & Amortization	0.17	0.12	0.02	0.02	0.02	0.02
Stock-Based Compensation	1.35	2.49	2.89	3.94	2.46	0
Other Adjustments	-6.56	-38.85	-2.8	14.94	7.94	0.1
Change in Receivables	-0.01	-1.01	0.01	-0.01	0.01	-0.03
Changes in Accounts Payable	-5.4	8.35	0.87	0.32	-1.75	3.9
Changes in Accrued Expenses	1.34	-0.53	0.26	0.17	-0.98	-
Changes in Other Operating Activities	2.11	2.94	-5.8	-0.98	-0.13	-0.29
Operating Cash Flow	-27.42	-33.32	-31.33	-16	-9.67	-1.7
Capital Expenditures	-	-0.63	-	-	-	-
Other Investing Activities	-0.28	-0.31	-	-	-	-
Investing Cash Flow	-0.28	-0.94	-	-	-	-
Short-Term Debt Issued	-	-	-	-	-	0.55
Short-Term Debt Repaid	-	-	-	-	-0.3	-
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-0.3	0.55
Long-Term Debt Issued	-	-	-	-	0.27	-
Long-Term Debt Repaid	-	-	-	-	-0.38	-0.52
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-0.11	-0.52
Issuance of Common Stock	42.28	6.1	5.28	8.34	81.51	1.54
Repurchase of Common Stock	-	-	-0.06	-13.04	-	-
Net Common Stock Issued (Repurchased)	42.28	6.1	5.22	-4.69	81.51	1.54
Other Financing Activities	-	-	-	-0.1	-	-
Financing Cash Flow	42.28	6.1	5.22	-4.8	81.1	1.57
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-	-0.06
Net Cash Flow	13.94	-28.15	-26.11	-20.8	71.43	-0.12
Free Cash Flow	-20.05	-24.58	-23.74	-12.48	-7.75	-1.27
Free Cash Flow Per Share	-85.31	-224.09	-228.03	-120.86	-257.22	-265.99
Levered Free Cash Flow	-7.42	2.34	-23.82	-27.2	-16.42	-1.3
Unlevered Free Cash Flow	-24.25	-25.92	-26.79	-15.65	-9.25	-1.24

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q